* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Guidelines for Animal Research Involving Viral Vectors
Survey
Document related concepts
Transcript
GUIDELINES FOR ANIMAL RESEARCH INVOLVING VIRAL VECTORS General Containment Commercial vector systems often come with a suggested biological safety containment level. A higher containment level may be required depending on the specific properties of the vector and/or the insert of interest. Additional safety considerations should be given to the design and use of viral vectors containing potentially hazardous genes such as oncogenes, tumor suppressors, growth regulating products, etc. This document provides general guidelines for animal biosafety containment for common viral vectors. The biological safety level and containment requirements are ultimately determined by the Institutional Biosafety Committee (IBC) and exceptions to these guidelines can be reviewed on a case by case basis. ADENO-ASSOCIATED VIRUS VECTORS Adeno-Associated virus (AAV) is a parvovirus infectious to humans and some other primate species. It is not known to have any disease association, causes a mild immune response, and some AAV types are commonly found in the general population. These viruses have the ability to integrate into a specific site on chromosome 19. Adenoassociated virus vector is replication incompetent and transduces dividing and non-dividing cells. It does not cause disease. AVV vectors have also been rendered integration incompetent; the transferred DNA exists episomally. AAV vectors have only a limited capacity to carry and transfer genes of interest. If the transferred gene does not encode either a potentially tumorigenic gene product or toxin molecule, and the AAV vector is produced in the absence of a helper virus, it can usually be handled at biosafety level 1. Laboratory Hazards • • Inhalation of aerosolized droplets, mucous membrane contact, parenteral injection, or ingestion. There is no specific treatment for infection with AAV. Animal Biosafety Containment • • • • • AAV vector can be administered under ABSL1 containment. Animal housing maintained at ABSL1. ABSL2 if helper virus is present. Label cages with agent description. Biohazard sticker is not required. Use microisolator top cages for 7 days after the final administration of viral vector. Disposal and Decontamination • • • Autoclave bedding/cages if initial cage change or cage change is within 7 days post final administration prior to disposal or washing. Dispose of carcasses as pathology waste. Use 10% household bleach solution or other appropriate EPA approved disinfectant, or autoclave for 30 minutes at 121ºC under 15 lbs per square inch of steam pressure. ADENOVIRUS VECTORS Adenoviruses are infectious to humans and animals and often cause mild respiratory illness, pink eye or gastroenteritis (stomach flu). In rare cases, particularly in immunocompromised individuals, severe disease can occur. Adenovirus and adenoviral vectors can infect a wide range of mammalian cells and replicate as episomal elements in the nucleus of the host cell, not integrating into the host genome. The vector is recombinogenic if wild type adenovirus is somehow introduced into producer cell culture and can become replication competent. Laboratory Hazards • • Inhalation of aerosolized droplets, mucous membrane contact, parenteral injection, or ingestion. Adenovirus is stable in the environment. Animal Biosafety Containment • • • • Adenovirus vector must be administered under ABSL2 containment with use of a biosafety cabinet. Animals may shed/excrete adenovirus post-administration. Animals must be housed under ABSL2 conditions for 7 days post final administration, after which animals may be housed at ABSL1. Label cages with agent description. Biohazard sticker is required. Use microisolator top cages for 7 days after the final administration of viral vector. Disposal and Decontamination • Autoclave bedding/cages if initial cage change or cage change is within 7 days post final administration prior to disposal or washing. • • Dispose of carcasses as pathology waste. Use 10% household bleach solution or other appropriate EPA approved disinfectant, or autoclave for 30 minutes at 121ºC under 15 lbs per square inch of steam pressure. RETROVIRUS/MURINE LEUKEMIA VIRUS (MLV) VECTORS Moloney Murine Leukemia Virus, short MMLV or MLV, is a retrovirus that infects actively diving cells and integrates in the host genome. While the wild-type virus is oncogenic in mice, it is not known to cause clinical manifestations of disease in humans. The host range of MLV or MMLV vectors is dependent on the specificity of the viral envelope. Pseudotyping directs tropism (e.g. ecotropic – infects mouse cells, amphotropic – infects human and mouse cells, VSV-G – vesicular stomatitis virus G protein - infects all mammalian and other vertebrate cells = pantropic). MLV vectors have a large gene carrying capacity. They only transduce dividing cells, which can be seen as an advantage or disadvantage for certain applications. MLV vectors integrate semi randomly into start regions of active genes in the host chromosome, which poses a risk of insertional mutagenesis and oncogenesis. Gene expression by MLVbased vectors can be shut down in human cells over time. Laboratory Hazards • • In mice, virus is transmitted via blood from infected mother to offspring; may also occur via germline infection. Infection in humans appears to require direct parenteral injection with amphotropic or pseudotyped MLV. Animal Biosafety Containment • • Ecotropic MLV vector can be administered under ABSL1 containment. Amphotropic or pseudotyped MLV vector must be administered under ABSL2 containment with use of a biosafety cabinet. • • • If using amphotropic or pseudotyped MLV vector, animals must be housed under ABSL2 conditions for 48 hours post final administration, after which animals may be housed at ABSL1. Label cages with agent description. Biohazard sticker is required for amphotropic or pseudotyped MLV. Use microisolator top cages for 48 hours after the final administration of viral vector. Disposal and Decontamination • • • Autoclave bedding/cages if initial cage change or cage change is within 48 hours post final administration prior to disposal or washing. Dispose of carcasses as pathology waste. Use 10% household bleach solution or other appropriate EPA approved disinfectant, or autoclave for 30 minutes at 121ºC under 15 lbs per square inch of steam pressure. LENTIVIRUS VECTORS Lentiviruses are a subset of retroviruses. HIV-1 is the best known example of this subset of retroviridae and is the cause of AIDS in humans. They integrate into active genes in the host cell chromosomes, but not into transcriptional start regions. They can infect dividing and non-dividing cells. They have the potential of causing insertional mutagenesis. They express their genes in a stable fashion long term. Just as the wild type viruses, lentiviral vectors transduce both dividing and non-dividing cells. They semi-randomly integrate into the host genome, but their integration patterns are much safer than the integration patterns of MLV vectors, since they do not integrate into transcriptional start regions. Therefore, activation of oncogenes in cis is less prevalent. They can still cause insertional mutagenesis, however. They have a large gene carrying capacity and provide stable, long term gene expression in human cells. Lentivectors are mainly pseudotyped with VSV-G, which makes them pantropic. Lentivectors are mainly pseudotyped with VSV-G, which makes them pantropic. Production systems for lentivectors are commercially available in 3 or 4 plasmid systems to lower the risk for recombination and production of replication-competent lentivectors in the producer cells. However, generation of replication-competent lentivector cannot be completely excluded and needs to be verified. It has, however, never occurred since the inception of these systems. Post Exposure Prophylaxis with antiretroviral drugs can be considered if there has been an exposure incident with lentiviral vectors under the direction of the Occupational Health Physician. Laboratory Hazards • Direct contact with skin and mucous membranes, parenteral injection, or ingestion. Animal Biosafety Containment • • • • Lentivirus vector must be administered under ABSL2 containment with use of a biosafety cabinet. Additional containment requirements may be necessary depending on the gene insert. Animals must be housed under ABSL2 conditions for 48 hours post final administration, after which animals may be housed at ABSL1. Label cages with agent description. Biohazard sticker is required. Use microisolator top cages for 48 hours after the final administration of viral vector. Disposal and Decontamination • • • Autoclave bedding/cages if initial cage change or cage change is within 48 hours post final administration prior to disposal or washing. Dispose of carcasses as pathology waste. Use 10% household bleach solution or other appropriate EPA approved disinfectant, or autoclave for 30 minutes at 121ºC under 15 lbs per square inch of steam pressure. Viral Vector AdenoAssociated Virus (AAV) Risk Group Animal Biosafety Level Special Handling Requirements *** Hold Caging during Labeling Period** hold period Label with description of agent and dose 1 ABSL1 7 days Microisolator lid Biohazard sticker not required Adenovirus 2 ABSL2 7 days Microisolator lid Label with description of agent and dose Biohazard sticker required Retrovirus/ Murine Leukemia Virus (MLV) Label with description of agent and dose 1 / 2* ABSL1 / ABSL2* 48 hours Microisolator lid Lentivirus 2 ABSL2 48 hours Microisolator lid Biohazard sticker required for amphotropic or pseudotyped Label with description of agent and dose Biohazard sticker required Carcass Disposal Biohazard (Pathology) Waste Biohazard (Pathology) Waste Bedding/Cage Disposal **** Autoclave bedding and cages prior to disposal/washing during hold period After hold, discard as standard waste Autoclave bedding and cages prior to disposal/washing during hold period After hold, discard as standard waste Biohazard (Pathology) Waste Autoclave bedding and cages prior to disposal/washing during hold period After hold, discard as standard waste Biohazard (Pathology) Waste Autoclave bedding and cages prior to disposal/washing during hold period After hold, discard as standard waste *If amphotropic or pseudotyped ** Holding time that must be observed before animals can be downgraded to ABSL1 housing *** Special handling requirements for non-rodents (for example: livestock and primates) may vary or differ from these guidelines. Specific procedures must be approved by the IBC. **** Autoclave initial cage change regardless of hold period